Ixazomib

Ixazomib FDA approved ixazomib (NINLARO, Millennium Pharmaceuticals, Inc., a wholly owned subsidiary of Takeda Pharmaceutical Company Limited) in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received at least one prior therapy. Ixazomib is the first approved oral proteasome inhibitor. November 20, 2015. More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm473804.htm

Carfilzomib FDA Approved

FDA approved carfilzomib (Kyprolis, Onyx Pharmaceuticals, Inc., an Amgen subsidiary) in combination with lenalidomide and dexamethasone for the treatment of patients with relapsed multiple ymemloa who have received one to three prior lines of therapy. July 24, 2015.  More Information: http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm455873.htm Disclaimer: The EDC Developer blog is “one man’s opinion”. Anything that is said on theContinue reading “Carfilzomib FDA Approved”